Top-Rated StocksTop-RatedNASDAQ:RLAY Relay Therapeutics (RLAY) Stock Price, News & Analysis → Strange new buyer driving up gold (From Stansberry Research) (Ad) Free RLAY Stock Alerts $5.96 -0.15 (-2.45%) (As of 03:34 PM ET) Add Compare Share Share Today's Range$5.92▼$6.3450-Day Range$6.11▼$10.8452-Week Range$5.92▼$13.32Volume1.29 million shsAverage Volume1.13 million shsMarket Capitalization$781.83 millionP/E RatioN/ADividend YieldN/APrice Target$23.30 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Relay Therapeutics alerts: Email Address Relay Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside287.0% Upside$23.30 Price TargetShort InterestBearish8.52% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.49Based on 2 Articles This WeekInsider TradingSelling Shares$43,814 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.84) to ($2.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.75 out of 5 starsMedical Sector522nd out of 918 stocksBiological Products, Except Diagnostic Industry77th out of 151 stocks 3.4 Analyst's Opinion Consensus RatingRelay Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRelay Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.52% of the outstanding shares of Relay Therapeutics have been sold short.Short Interest Ratio / Days to CoverRelay Therapeutics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Relay Therapeutics has recently decreased by 5.42%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRelay Therapeutics does not currently pay a dividend.Dividend GrowthRelay Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RLAY. Previous Next 1.4 News and Social Media Coverage News SentimentRelay Therapeutics has a news sentiment score of -0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Relay Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for RLAY on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows10 people have added Relay Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Relay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,814.00 in company stock.Percentage Held by InsidersOnly 3.54% of the stock of Relay Therapeutics is held by insiders.Percentage Held by Institutions96.98% of the stock of Relay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Relay Therapeutics are expected to grow in the coming year, from ($2.84) to ($2.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relay Therapeutics is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relay Therapeutics is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelay Therapeutics has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchStrange new buyer driving up goldOne Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."But there's a much better move you can make to get in front of these big moves today. About Relay Therapeutics Stock (NASDAQ:RLAY)Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More RLAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RLAY Stock News HeadlinesApril 11, 2024 | globenewswire.comRelay Therapeutics to Participate in Upcoming Investor ConferencesApril 11, 2024 | americanbankingnews.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Rating of "Moderate Buy" from AnalystsApril 19, 2024 | Stansberry Research (Ad)Strange new buyer driving up goldOne Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."March 19, 2024 | markets.businessinsider.comStrong Buy Rating for Relay Therapeutics Amid Pipeline Progress and Strategic DirectionMarch 16, 2024 | finance.yahoo.comRLAY Apr 2024 7.500 callMarch 16, 2024 | finance.yahoo.comRLAY Apr 2024 7.500 putMarch 15, 2024 | investorplace.com3 Precision Medicine Stocks That Could Benefit From the Industry's RiseMarch 13, 2024 | seekingalpha.comRelay Therapeutics: Platform More Important Than ProgramsApril 19, 2024 | Stansberry Research (Ad)Strange new buyer driving up goldOne Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."February 26, 2024 | globenewswire.comRelay Therapeutics to Participate in Three Upcoming Investor ConferencesFebruary 26, 2024 | markets.businessinsider.comRelay Therapeutics: Strong Buy on Improved Financials and Promising Future MilestonesFebruary 25, 2024 | fool.comRelay Therapeutics (NASDAQ: RLAY)February 24, 2024 | finance.yahoo.comRelay Therapeutics Full Year 2023 Earnings: Beats ExpectationsFebruary 23, 2024 | finanznachrichten.deRelay Therapeutics, Inc.: Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate HighlightsFebruary 22, 2024 | markets.businessinsider.comOptimistic Buy Rating for Relay Therapeutics: Strong Financial Standing and Strategic Pipeline FocusFebruary 22, 2024 | finance.yahoo.comRelay Therapeutics Inc (RLAY) Reports Full Year 2023 Financial Results and Corporate HighlightsFebruary 22, 2024 | globenewswire.comRelay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate HighlightsFebruary 21, 2024 | benzinga.comRelay Therapeutics's Earnings: A PreviewFebruary 21, 2024 | investing.comRelay Therapeutics Inc (RLAY)February 17, 2024 | finance.yahoo.comRLAY Mar 2024 7.500 putFebruary 16, 2024 | finance.yahoo.comVERV Mar 2024 12.500 callFebruary 15, 2024 | finance.yahoo.comRelay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024February 15, 2024 | globenewswire.comRelay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024February 15, 2024 | markets.businessinsider.comRelay Therapeutics Poised for Growth with Promising RLY-2608, Analyst Maintains Buy RatingFebruary 15, 2024 | finance.yahoo.comRelay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?February 12, 2024 | seekingalpha.comRelay Therapeutics: Tapping Into An Unmet Need At A High Price TagFebruary 1, 2024 | finance.yahoo.comRelay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceSee More Headlines Receive RLAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/19/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:RLAY CUSIPN/A CIK1812364 Webwww.relaytx.com Phone617-370-8837FaxN/AEmployees323Year FoundedN/APrice Target and Rating Average Stock Price Target$23.30 High Stock Price Target$33.00 Low Stock Price Target$12.50 Potential Upside/Downside+287.7%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-341,970,000.00 Net Margins-1,263.49% Pretax Margin-1,338.66% Return on Equity-42.43% Return on Assets-36.47% Debt Debt-to-Equity RatioN/A Current Ratio25.44 Quick Ratio25.44 Sales & Book Value Annual Sales$25.55 million Price / Sales31.37 Cash FlowN/A Price / Cash FlowN/A Book Value$5.90 per share Price / Book1.04Miscellaneous Outstanding Shares131,180,000Free Float126,535,000Market Cap$801.51 million OptionableOptionable Beta1.63 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Alexis A. Borisy A.M. (Age 52)Co-Founder & Independent Chairman Comp: $85kDr. Sanjiv K. Patel M.A. (Age 50)M.B.A., M.D., MBBS, CEO, President & Director Comp: $1.03MDr. Mark Murcko Ph.D. (Age 64)Co-Founder & Director Comp: $50kMr. Thomas Catinazzo (Age 47)Chief Financial Officer Comp: $599.83kMr. Brian R. Adams J.D. (Age 50)Chief Legal Officer & Secretary Comp: $598.53kDr. Donald A. Bergstrom M.D. (Age 52)Ph.D., President of Research & Development Comp: $711.25kMr. Peter RahmerChief Corporate Development OfficerDr. Deborah Palestrant M.B.A.Ph.D., Vice President of Corporate Development & StrategyMr. Jim Watters Ph.D.Chief Scientific Officer of Late ResearchDr. Beni B. Wolf M.D.Ph.D., Chief Medical Officer & Head of Precision MedicineMore ExecutivesKey CompetitorsImmaticsNASDAQ:IMTXREGENXBIONASDAQ:RGNXBioCryst PharmaceuticalsNASDAQ:BCRXCARGO TherapeuticsNASDAQ:CRGXCabaletta BioNASDAQ:CABAView All CompetitorsInsiders & InstitutionsMesirow Financial Investment Management Inc.Bought 17,627 shares on 4/19/2024Ownership: 0.013%Allspring Global Investments Holdings LLCBought 9,569 shares on 4/18/2024Ownership: 0.007%TrueMark Investments LLCBought 6,487 shares on 4/15/2024Ownership: 0.042%Congress Asset Management Co. MABought 2,108 shares on 4/11/2024Ownership: 0.114%Los Angeles Capital Management LLCBought 2,850 shares on 4/5/2024Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions RLAY Stock Analysis - Frequently Asked Questions Should I buy or sell Relay Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RLAY shares. View RLAY analyst ratings or view top-rated stocks. What is Relay Therapeutics' stock price target for 2024? 6 analysts have issued 12 month price objectives for Relay Therapeutics' shares. Their RLAY share price targets range from $12.50 to $33.00. On average, they anticipate the company's share price to reach $23.30 in the next year. This suggests a possible upside of 287.0% from the stock's current price. View analysts price targets for RLAY or view top-rated stocks among Wall Street analysts. How have RLAY shares performed in 2024? Relay Therapeutics' stock was trading at $11.01 at the beginning of the year. Since then, RLAY stock has decreased by 45.3% and is now trading at $6.02. View the best growth stocks for 2024 here. When is Relay Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our RLAY earnings forecast. How were Relay Therapeutics' earnings last quarter? Relay Therapeutics, Inc. (NASDAQ:RLAY) issued its quarterly earnings data on Thursday, February, 22nd. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($0.76) by $0.09. Relay Therapeutics had a negative net margin of 1,263.49% and a negative trailing twelve-month return on equity of 42.43%. During the same period in the prior year, the business earned ($0.56) earnings per share. What ETFs hold Relay Therapeutics' stock? ETFs with the largest weight of Relay Therapeutics (NASDAQ:RLAY) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).TrueShares Technology, AI & Deep Learning ETF (LRNZ). What other stocks do shareholders of Relay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Relay Therapeutics investors own include Beyond Meat (BYND), CureVac (CVAC), QuidelOrtho (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG), DraftKings (DKNG), eHealth (EHTH), GoHealth (GOCO) and Intel (INTC). When did Relay Therapeutics IPO? Relay Therapeutics (RLAY) raised $250 million in an IPO on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO. Who are Relay Therapeutics' major shareholders? Relay Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Congress Asset Management Co. MA (0.11%), TrueMark Investments LLC (0.04%), Mesirow Financial Investment Management Inc. (0.01%), Los Angeles Capital Management LLC (0.01%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Andy Porter, Brian Adams, Donald A Bergstrom, Mark Murcko, Peter Rahmer, Sanjiv Patel and Thomas Catinazzo. View institutional ownership trends. How do I buy shares of Relay Therapeutics? Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RLAY) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIYour Money is Not SafeAmerican AlternativeHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceSHOCKING Crypto Leak…Crypto 101 MediaMy biggest AI fearParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.